Tempest Therapeutics, Inc.
TPST
$3.03
-$0.03-0.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.08% | 23.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -54.85% | -27.16% | |||
| Operating Income | 54.85% | 27.16% | |||
| Income Before Tax | 55.39% | 27.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 55.39% | 27.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 55.39% | 27.53% | |||
| EBIT | 54.85% | 27.16% | |||
| EBITDA | 55.30% | 27.32% | |||
| EPS Basic | 61.79% | 34.49% | |||
| Normalized Basic EPS | 61.79% | 34.49% | |||
| EPS Diluted | 61.79% | 34.49% | |||
| Normalized Diluted EPS | 61.79% | 34.49% | |||
| Average Basic Shares Outstanding | 16.75% | 10.63% | |||
| Average Diluted Shares Outstanding | 16.75% | 10.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||